Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPALA: Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis
NCT02702180Phase 2Completed
- Sponsor
- Savara
- Start
- Mar 2016
- Primary completion
- Apr 2019
- Modality
- Cytokines & Interferons
- Countries
- 18
01
Overview
A Phase 2 trial of molgramostim in autoimmune pulmonary alveolar proteinosis (aPAP), sponsored by Savara. Started Mar 2016; status: completed.
02
Drugs
molgramostim
03
Conditions
autoimmune pulmonary alveolar proteinosis (aPAP)
Beyond the preview
Go deeper on NCT02702180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02702180.